Sensydia has raised nearly $8m in a financing round for advancing its cardiac performance system (CPS) platform.

Led by Florida-based Orlando Health Ventures, the financing round saw participation from Frontier Venture Capital, Colle Capital and other investors.

Sensydia intends to use the funds to prepare for the commercialisation of CPS, the next-generation haemodynamic monitoring platform.

Sensydia president and CEO Anthony Arnold said: “We are thrilled to have the support of investors who share our vision for transforming heart failure management.

“This funding will enable us to accelerate our march to commercialisation by expanding development and operations for our CPS platform.”

The CPS platform has been designed to offer quick, safe and non-invasive cardiac performance assessment, which can be undertaken anywhere, avoiding the need to visit a catheterisation lab.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Using AI algorithms and ultra-sensitive biosensors, the platform provides multiple, non-invasive measurements, including cardiac output, pulmonary capillary wedge pressure, ejection fraction and pulmonary artery pressure, in a handheld device.

It is suitable for the operating room, ICU, clinic, ER, office, as well as home care settings.

The company stated that the platform uses waveform machine learning methods which have been trained to gold-standard measurements obtained from in-hospital catheterisation lab data.

In January last year, the CPS received Breakthrough Device Designation from the US Food and Drug Administration.

Orlando Health Heart and Vascular Institute president Farhan Khawaja said: “Non-invasive and real-time cardiac function measures will lead to early diagnosis and personalised care for heart disease.

“This technology has the potential to vastly improve patient lives by enabling faster and more affordable disease management, moving healthcare from the hospital setting into the patient’s home.”

Simultaneously, the company has announced that Orlando Health chief administrative officer Erick Hawkins will join its board of directors.